Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

被引：6

作者：

Najim, Omar ^{[1
,2
]}

Papadimitriou, Konstantinos ^{[1
,2
,3
]}

Broeckx, Glenn ^{[1
,2
,4
]}

Huizing, Manon ^{[2
,5
]}

Tjalma, Wiebren ^{[1
,2
,6
]}

机构：

[1] Univ Antwerp, Univ Antwerp Hosp, Multidisciplinary Breast Clin, Edegem, Belgium

[2] Univ Antwerp, Fac Med, Edegem, Belgium

[3] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium

[4] Antwerp Univ Hosp, Dept Pathol, Edegem, Belgium

[5] Antwerp Univ Hosp, Biobank, Edegem, Belgium

[6] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Edegem, Belgium

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

ESR1; liquid biopsy; next-generation sequencing; digital PCR; metastasized breast cancer; CIRCULATING TUMOR DNA; ACTIVATING ESR1 MUTATIONS; ACQUIRED-RESISTANCE; PLASMA; EVOLUTION; EMERGENCE; THERAPY;

D O I：

10.3389/fonc.2023.1221773

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.

引用

页数：12

共 60 条

[11] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial [J].

Chandarlapaty, Sarat ;

Chen, David ;

He, Wei ;

Sung, Patricia ;

Samoila, Aliaksandra ;

You, Daoqi ;

Bhatt, Trusha ;

Patel, Parul ;

Voi, Maurizio ;

Gnant, Michael ;

Hortobagyi, Gabriel ;

Baselga, Jose ;

Moynahan, Mary Ellen .

JAMA ONCOLOGY, 2016, 2 (10) :1310-1315

[12] Endocrine resistance in breast cancer - An overview and update [J].

Clarke, Robert ;

Tyson, John J. ;

Dixon, J. Michael .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :220-234

[13] Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor [J].

Clatot, Florian ;

Perdrix, Anne ;

Augusto, Laetitia ;

Beaussire, Ludivine ;

Delacour, Julien ;

Calbrix, Celine ;

Sefrioui, David ;

Viailly, Pierre-Julien ;

Bubenheim, Michael ;

Moldovan, Cristian ;

Alexandru, Cristina ;

Tennevet, Isabelle ;

Rigal, Olivier ;

Guillemet, Cecile ;

Leheurteur, Marianne ;

Gouerant, Sophie ;

Petrau, Camille ;

Thery, Jean-Christophe ;

Picquenot, Jean-Michel ;

Veyret, Corinne ;

Frebourg, Thierry ;

Jardin, Fabrice ;

Sarafan-Vasseur, Nasrin ;

Di Fiore, Frederic .

ONCOTARGET, 2016, 7 (46) :74448-74459

[14] Cell-free circulating tumour DNA as a liquid biopsy in breast cancer [J].

De Mattos-Arruda, Leticia ;

Caldas, Carlos .

MOLECULAR ONCOLOGY, 2016, 10 (03) :464-474

[15] Liquid Biopsies: Genotyping Circulating Tumor DNA [J].

Diaz, Luis A. ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) :579-+

[16] The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].

Diaz, Luis A., Jr. ;

Williams, Richard T. ;

Wu, Jian ;

Kinde, Isaac ;

Hecht, J. Randolph ;

Berlin, Jordan ;

Allen, Benjamin ;

Bozic, Ivana ;

Reiter, Johannes G. ;

Nowak, Martin A. ;

Kinzler, Kenneth W. ;

Oliner, Kelly S. ;

Vogelstein, Bert .

NATURE, 2012, 486 (7404) :537-540

[17] Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib [J].

Ding, Pei N. ;

Becker, Therese ;

Bray, Victoria ;

Chua, Wei ;

Ma, Yafeng ;

Xu, Bo ;

Lynch, David ;

de Souza, Paul ;

Roberts, Tara .

THORACIC CANCER, 2019, 10 (10) :1879-1884

[18] ESR1 mutations in breast cancer [J].

Dustin, Derek ;

Gu, Guowei ;

Fuqua, Suzanne A. W. .

CANCER, 2019, 125 (21) :3714-3728

[19] Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA [J].

Forshew, Tim ;

Murtaza, Muhammed ;

Parkinson, Christine ;

Gale, Davina ;

Tsui, Dana W. Y. ;

Kaper, Fiona ;

Dawson, Sarah-Jane ;

Piskorz, Anna M. ;

Jimenez-Linan, Mercedes ;

Bentley, David ;

Hadfield, James ;

May, Andrew P. ;

Caldas, Carlos ;

Brenton, James D. ;

Rosenfeld, Nitzan .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (136)

[20] Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer [J].

Fribbens, Charlotte ;

O'Leary, Ben ;

Kilburn, Lucy ;

Hrebien, Sarah ;

Garcia-Murillas, Isaac ;

Beaney, Matthew ;

Cristofanilli, Massimo ;

Andre, Fabrice ;

Loi, Sherene ;

Loibl, Sibylle ;

Jiang, John ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Dowsett, Mitch ;

Bliss, Judith M. ;

Johnston, Stephen R. D. ;

Turner, Nicholas C. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2961-2968

← 1 2 3 4 5 6 →